
MorphoSys and Galapagos start Phase l study of MOR106
MorphoSys and Galapagos have commenced a Phase l trial to evaluate MOR106 for the treatment of moderate-to-severe atopic dermatitis.
MorphoSys and Galapagos have commenced a Phase l trial to evaluate MOR106 for the treatment of moderate-to-severe atopic dermatitis.
Thank you for subscribing to Clinical Trials Arena